跳至主要内容
临床试验/NCT05828732
NCT05828732招募中不适用

Clinical Feasibility of Disease-managing Mobile Application in the Patients With Hyperthyroidism

Seoul National University Bundang Hospital2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
2
主要终点
Scores of quality of life assessed by SF-36 survey

研究概览

简要总结

This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who have been newly diagnosed or are currently undergoing treatment for thyrotoxicosis at Bundang Seoul National University Hospital.
  • Subjects must be able to use the smartphone app required for the use of wearable devices and their integration.

排除标准

  • Subjects who have constraints on normal activity due to diseases other than thyroid dysfunction.
  • Subjects who are currently taking medication that affects heart rate.
  • Subjects with heart conditions such as arrhythmia that affect heart rate.
  • Subjects who cannot undergo antithyroid drug treatment and require surgery or radioactive iodine therapy.

结局指标

主要结局

Scores of quality of life assessed by SF-36 survey

时间窗: 14 weeks after baseline

Scores of quality of life assessed by SF-36 survey

antithyroidal drug compliance

时间窗: 14 weeks after baseline

Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.

Knowledge about hyperthyroidism

时间窗: 14 weeks after baseline

A score measured through a test designed to assess the knowledge level about Graves' disease

次要结局

  • free T4(14 weeks after baseline)
  • free T3(14 weeks after baseline)
  • TSH(14 weeks after baseline)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jae Hoon Moon

Professor

Seoul National University Bundang Hospital

研究点 (2)

Loading locations...

相似试验